| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C20H22BrNO3 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
YS-49 monohydrate is a PI3K/Akt activator, acting as a downstream target of RhoA to reduce RhoA/PTEN activation in 3-methylcholanthrene-treated cells. It also inhibits angiotensin II (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1, and, as an isoquinoline alkaloid compound, produces a strong positive inotropic action through activation of cardiac β-adrenoceptors[1][2][3]. It is supplied as an off-white to gray solid (C20H22BrNO3, MW 404.30) at 99.56% purity.
Physical & Chemical Properties
| CAS Number | 3028631-24-2 |
|---|---|
| Molecular Formula | C20H22BrNO3 |
| Molecular Weight | 404.30 g/mol |
| Purity | 99.56% |
| Appearance | Solid |
| Color | Off-white to gray |
| SMILES | OC1=CC2=C(C(CC3=C4C=CC=CC4=CC=C3)NCC2)C=C1O.O.Br |
| Signaling Pathway | PI3K/Akt/mTOR; GPCR/G Protein; Neuronal Signaling |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
In RAVSMC and RAW 264.7 cells exposed to lipopolysaccharide (LPS) plus INF-γ, YS-49 (1-100 μM; 18 hours; RAVSMC and RAW 264.7 cells) inhibits nitrite accumulation in a concentration-dependent manner, with IC50 values of 22 μM and 30 μM, respectively[2]. At the transcriptional level, YS-49 (10-100 μM; 18 hours; RAVSMC and RAW 264.7 cells) suppresses LPS- and/or cytokine-induced iNOS gene expression in RAVSMC and RAW 264.7 cells[2].
Cell Viability Assay[2]
| Cell Line | RAVSMC and RAW 264.7 cells |
|---|---|
| Concentration | 10 μΜ, 30 μΜ and 100 μΜ(RAVSMC); 1 μΜ, 10 μΜ and 100 μM (RAW 264.7) |
| Incubation Time | 18 hours |
| Result | Inhibited the accumulation of nitrite in both RAVSMC and RAW 264.7 exposed to LPS+INF-γ, with IC50 values of 22 and 30 μM, respectively. |
Western Blot Analysis[2]
| Cell Line | RAVSMC and RAW 264.7 cells |
|---|---|
| Concentration | 10 μΜ, 30 μΜ and 100 μΜ |
| Incubation Time | 18 hours |
| Result | Concentration-dependently inhibited the expression of iNOS protein induced by LPS plus IFN-γ. |
In Vivo
YS-49 (5 mg/kg; intraperitoneal injection; 8 hours; male Sprague Dawley rats) significantly lowers serum NOx levels in LPS-treated rats, from 86 μM to 34 μM[2].
| Animal Model | Male Sprague Dawley rats (250-300 g)[2] |
|---|---|
| Dosage | 5 mg/kg |
| Administration | Intraperitoneal injection; 8 hours |
| Result | Serum NOx levels were significantly reduced. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity. Signal Transduct Target Ther 2021 Jun 18;6(1):234. PMID: 34140465
Integrating spatial transcriptomics and single-nucleus RNA-seq revealed the specific inhibitory effects of TGF-β on intramuscular fat deposition. Sci China Life Sci 2025 Mar;68(3):746-763. PMID: 39422812
PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh9. Mol Ther Oncolytics 2022 Aug 5:26:360-371. PMID: 36090473
Mater Des. 2026 May 30;267:116311.
"γδT Cell-IL17A-Neutrophil" Axis Drives Immunosuppression and Confers Breast Cancer Resistance to High-Dose Anti-VEGFR2 Therapy. Front Immunol 2021 Oct 15;12:699478. PMID: 34721375
Huangqin Qingre Chubi Capsule modulates the lncRNA AP005432.1/PI3K/AKT axis and is associated with improved self-perception of patients and inflammation in ankylosing spondylitis. J Ethnopharmacol 2026 Jul 15:366:121662. PMID: 41956229
Columbianadin suppresses glioblastoma progression by inhibiting the PI3K-Akt signaling pathway. Biochem Pharmacol 2024 May:223:116112. PMID: 38458331
Chinese herbal compound Huangqin Qingrechubi capsule reduces lipid metabolism disorder and inflammatory response in gouty arthritis via the LncRNA H19/APN/PI3K/AKT cascade. Pharm Biol 2023 Dec;61(1):541-555. PMID: 36994890
DTX1-mediated degradation of TUBB3 in Kupffer cells mitigates hepatocellular carcinoma progression by regulating M1/M2 polarization. Commun Biol 2026 Jan 23;9(1):311. PMID: 41577987
Mechanism of β‑sitosterol in treating keloids: Network pharmacology, molecular docking and experimental verification. Mol Med Rep 2025 Apr;31(4):95. PMID: 39981895
